France
Brenus Pharma, established in 2019 and headquartered in France, is a cutting-edge clinical-stage biotech firm focused on eradicating cancer recurrence, a significant challenge in solid tumor treatment contributing to 10 million deaths annually. Their innovative platform offers "off-the-shelf" therapeutic solutions, positioning the immune system ahead of cancer.
Their flagship candidate targets colorectal cancer (CRC), the second most lethal cancer globally. The platform leverages proteomics-driven immunotherapy to deliver more potent, diverse, and novel targets than existing treatments. Their approach surpasses the limitations of technologies like mRNA vaccines by enhancing immunogenicity and maintaining cost-efficient, standardized GMP manufacturing processes.
In 2024, Brenus Pharma was honored as "Best Biotech Startup" in France and secured a $25 million Series A investment from notable backers including Angelor, UI Investissement, and others. The company is actively pursuing clinical collaborations, heralding a paradigm shift in oncology treatment.
